Synthetic ACTH fragment analog neuropeptide (approved in Russia/Ukraine)
N-acetyl Semax
An ACTH-derived peptide studied for cognitive enhancement and neuroprotection; human evidence is region-specific.
- Evidence:
- Limited human evidence
- Status:
- Approved outside the U.S. (context-specific)
- Reviewed:
- 2026-08-03
Also known as: N-acetyl Semax, ACTH 4-10 analog
What is N-acetyl Semax?
An ACTH-derived peptide studied for cognitive enhancement and neuroprotection; human evidence is region-specific.
This profile is educational. It organizes publicly discussed research context for N-acetyl Semax and related naming aliases — it is not a treatment guide.
Proposed mechanism
Proposed upregulation of BDNF and NGF, modulation of dopaminergic and serotonergic systems, and neuroprotective signaling.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Limited human evidence
Preclinical evidence grade: Moderate human evidence
Semax is approved in Russia and Ukraine for stroke and cognitive indications. Russian trials report cognitive improvements. Western replication is limited. Intranasal route commonly discussed. Nasal bioavailability for many peptides is poorly characterized in published Western literature. Often compared to nootropic research compounds.
Key uncertainties
- Generalizability of cognitive effects
- Long-term intranasal use safety
Research areas being studied
- Stroke recovery
- Cognitive enhancement
- ADHD research
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Irritation with intranasal use
- Generally mild in approved market studies
Additional risks & considerations
- Limited independent Western trials
- Unregulated analog products
Regulatory status
Approved outside the U.S. (context-specific)
Approved in Russia/Ukraine; not FDA approved.
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is N-acetyl Semax?
An ACTH-derived peptide studied for cognitive enhancement and neuroprotection; human evidence is region-specific.
How does N-acetyl Semax work (proposed mechanism)?
Proposed upregulation of BDNF and NGF, modulation of dopaminergic and serotonergic systems, and neuroprotective signaling.
What is N-acetyl Semax being researched for?
N-acetyl Semax has been discussed in research contexts including: Stroke recovery, Cognitive enhancement, ADHD research.
What does current evidence say about N-acetyl Semax?
Limited human evidence. Semax is approved in Russia and Ukraine for stroke and cognitive indications. Russian trials report cognitive improvements. Western replication is limited. Intranasal route commonly discussed. Nasal bioavailability for many peptides is poorly characterized in published Western literature. Often compared to nootropic research compounds.
What safety considerations are noted for N-acetyl Semax?
Reported or discussed considerations include: Irritation with intranasal use; Generally mild in approved market studies; Limited independent Western trials; Unregulated analog products. This is educational information, not medical advice.
Is N-acetyl Semax FDA approved?
Approved outside the U.S. (context-specific). Approved in Russia/Ukraine; not FDA approved.
References & sources
- Gusev EI et al. (1997). Semax in ischemic stroke recovery — Zh Nevrol Psikhiatr. Evidence type: human.
Prefer interactive tools? Open the PepGuide library entry for N-acetyl Semax or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.